This work may not be copied, distributed, displayed, published, reproduced, transmitted, modified, posted, sold, licensed, or used for commercial purposes. By downloading this file, you are agreeing to the publisher’s Terms & Conditions.

Correction

Correction: Oral Ketamine for Depression

Joshua D. Rosenblat, MD; Andre F. Carvalho, MD, PhD; Madeline Li, MD, PhD; Yena Lee,BSc; Mehala Subramanieapillai, MSc; and Roger S. McIntyre, MD

Published: April 22, 2020

Correction

In the article “Oral Ketamine for Depression: A Systematic Review” by Joshua D. Rosenblat, MD; Andre F. Carvalho, MD, PhD; Madeline Li, MD, PhD; Yena Lee, BSc; Mehala Subramanieapillai, MSc; and Roger S. McIntyre, MD, published in the May/June 2019 issue (J Clin Psychiatry 2019;80[3]:18r12475), and the letter “Drs Rosenblat and McIntyre Reply” by Joshua D. Rosenblat, MD, and Roger S. McIntyre, MD, published in the January/February 2020 issue (J Clin Psychiatry 2020;81[1]:19lr13146a), conflict of interest information for Drs Rosenblat and McIntyre has been corrected to show that Dr McIntyre is the director of and Dr Rosenblat is a staff psychiatrist at a clinic that administers intravenous ketamine, and Dr McIntyre has been on advisory boards and/or received honoraria for educational activities and/or research grants from Takeda, Neurocrine, Allergan, and Sunovion.

Volume: 81

Quick Links: Depression (MDD)

References

Sign-up to stay
up-to-date today!

SUBSCRIBE

Already registered? Sign In

Case Report

Safety and Tolerability of Concomitant Intranasal Esketamine Treatment With Irreversible, Nonselective MAOIs: A Case Series

Three cases suggest that concomitant use of intranasal esketamine with an irreversible, nonselective MAOI is safe in...

Read More...